ERK Inhibition by SU1498 Alters Expression of Bcl‐2 Family Proteins in Breast Cancer Cells

Abstract

The extracellular signal‐regulated kinase (ERK) pathway is vital to the cell survival. We have demonstrated the ability of SU1498, an inhibitor of ERK kinase activity, to sensitize breast cancer cells with constitutively active ERK to apoptosis. To identify the mechanisms involve, the expression of the antiapoptotic Bcl‐2 and Bcl‐xL and the proapoptotic Bad, Bax, Bik and Bak were examined under apoptotic conditions. One breast cell line (MCF‐10A) and three breast cancer cell lines (MCF 7, MDA‐MB‐231 and MDA‐MB‐468) were used to examine the effects of SU1498 and serum starvation on the expression of the Bcl‐2 family proteins. The MCF‐10A and MCF7 cells exhibit normal ERK regulation while the MDA‐MB‐231 and MDA‐MB‐468 cells lines have a constitutively activated ERK. Across all the cell lines, the combined treatments resulted in either decreased expression, or no changes in the expression, of the antiapoptotic Bcl2 proteins. The expression of the proapoptotic proteins Bad or Bak were dramatically upregulated only in those cells with constitutive ERK activation, while they tended to demonstrate reduced expression in the cells lines with normal ERK regulation. These cell lines with upregulate Bad and/or Bak expression were also those most sensitive to SU1498 induced cell death. The ability of SU1498 to sensitize breast cancer cells to apoptosis by inhibition of ERK may have therapeutic uses.Supported by NSERC